Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

 Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

Tessa Collaborates with Merck to Evaluate a Combination Therapy for Metastatic or Recurrent Cervical Cancer

Shots:

  • Tessa to conduct a P-Ib/II trial assessing Tessa’s human papillomavirus-specific T cell (HPVST) therapy or TT12 with Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic HPV 16 and 18-positive cervical cancer
  • The P-Ib/II trial will be initiated in the US, Singapore, South Korea. Additionally, Tessa’s TT12 and an anti PD-1 therapy is being evaluated in P-I for patients with relapsed HPV-associated cancers, resulted in well-tolerated and minimal toxicity results in the US
  • Tessa’s TT12 is an autologous cell therapy based on HPVSTs targeting HPV 16/18 antigens and genetically modified with a decoy TGF-β receptor. Keytruda (pembrolizumab) is an anti-PD-1 therapy involves blocking of the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2

Click here to read full press release/ article | Ref: Tessa Therapeutics | Image: WSJ

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post